LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The ultimate clinical aim of this proposed phase I trial is to evaluate the toxicity and
determine the recommended phase II dose of combining the effect of LDFWART following
administration of docetaxel for 6 cycles in patients with recurrent platinum-resistant
ovarian cancer.